Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype

AIDS Research and Human Retroviruses

Volumn 12, Issue 2, 1996, Pages 83-90

  Bhattacharyya, Dhananjay ^a,c   Brooks, Bernard R ^a   Callahan, Larry ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNITED STATES PHARMACOPEIA   (United States)

^c SAHA INSTITUTE OF NUCLEAR PHYSICS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; SUGAR;

ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR INTERACTION; NONHUMAN; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; SYNCYTIUM; VIRUS STRAIN;

EID: 0030071595     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.83     Document Type: Article

References (48)

1. Fenyo EM, Morfeldt ML, Chiodi F, Lind B, von Gegerfelt A, Albert J, Olausson E, and Asjo B: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62:4414-4419.
2. Asjo B, Morfeldt-Manson L, Albert J, Bilberfeld G, Karlsson A, Lidman K, and Fenyo EM: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986;2:660-662.
3. Cheng-Mayer C, Seto D, Tateno M, and Levy J: Biologic features of HIV-1 that correlate with virulence in the host. Science 1988;240:80-82.
4. Tersmette M, Lange JM, de Goede PE, de Wolf F, Eeftink-Schattenkerk JK, Schellekens PT, Coutinho PA, Huisman JG, Goudsmit J, and Miedema F: Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989;1:983-985.
5. McNearney T, Homickara Z, Markham R, Birdwell A, Arens M, Sach A, and Ratner L: Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci USA 1992;89:10247-10251.
6. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwilj RP, Lange JM, Schattenkerk JK, Miedema F, and Tersmette M: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-1360.
7. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, and Tersmette M: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-688.
8. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, Goudsmit J, Huisman HG, and Miedema F: Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J Virol 1989; 63:2118-2125.
9. York-Higgins D, Cheng-Mayer CC, Bauer D, Levy JA, and Dina D: Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol 1990;64:4016-4020.
10. O'Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, Idler K, Zack JA, and Chen IS: HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (London) 1990;348:69-73.
11. Shioda T, Levy JA, and Cheng-Mayer C: Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (London) 1991;349:167-169.
12. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-74.
13. de Jong JJ, Goudsmit J, Keulen W, Klaver B, Krone W, Tersmette M, and de Ronde A: Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992;66:757-765.
14. Fouchier RA, Groenick M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, and Schuitemaker H: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66:3183-3187.
15. Kuiken CL, de Jong JJ, Baan E, Keulen W, Tersmette M, and Goudsmit J: Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 1992; 66:4622-4627.
16. Milch L, Margolin B, and Swanstrom R: V3 loop of the human immunodeficiency virus type 1 Env protein: Interpreting sequence variability. J Virol 1993;67:5623-5634.
17. Groenink M, Fouchier RA, Broersen S, Baker CH, Koot M, van't Wout AB, Huisman HG, Miedema F, Tersmette M, and Schuitemaker H: Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993;260;1513-1516.
18. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Holley LH, Karplus M, Bolognesi DP, Matthews TJ, Emini EA, and Putney SD: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249: 932-935.
19. Chandrasekhar K, Profy AT, and Dyson HJ: Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120. Biochemistry 1991;30:9187-9194.
20. Gupta G, Anantharamaiah GM, Scott DR, Eldridge JH, and Meyers G: Solution structure of the V3 loop of a Thailand HIV isolate. J Biomol Struct Dyn 1993;11:345-366.
21. de Lorimier R, Moody MA, Haynes BF, and Spicer LD: NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus. Biochemistry 1994; 33:2055-2062.
22. Rini JM, Stanfield RL, Stura EA, Salinas PA, Profy AT, and Wilson IA: Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc Natl Acad Sci USA 1993;90:6325-6329.
23. Ghiara JB, Stura EA, Stanfield RL, Profy AT, and Wilson IA: Crystal structure of the principal neutralization site of HIV-1. Science 1994;264:82-85.
24. Venable RM, Pastor RW. Brooks BR, and Carson FW: Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein. AIDS Res Hum Retroviruses 1989;5:7-22.
25. Johnson ME, Lin Z, Padmanabhan K, Tulinsky A, and Khan M: Conformational rearrangements required of the V3 loop of HIV-1 gp!20 for proteolytic cleavage and infection. FEBS Lett 1994;337:4-8.
26. Cardin AD, Demeter DA, Weintraub HJR, and Jackson RL: Molecular design and modeling of protein-heparin interactions. Methods Enzymol 1991;203:556-583.
27. Schols D, Pauwels R, Desmyter J, and De Clercq E: Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 1990;175:556-560.
28. Callahan LN, Phelan M, Mallinson M, and Norcross MA: Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol 1991;65:1543-1550.
29. Rider CC, Coombe DR, Harrop HA, Hounsell EF, Bauer C, Feeney J, Mulloy B, Mahmood N, Hay A, and Parish CR: Anti-HIV-1 activity of chemically modified heparans: Correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 1994;33:6974-6980.
30. Meylan PRA, Kornbluth RS, Zbinden I, and Richman DD: Influence of host cell type and V3 loop of the glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds. Antimicrob Agents Chemother 1994;38:2910-2916.
31. Callahan L: HIV-1 virion-cell interactions: An electrostatic model of pathogenecity and syncytium formation. AIDS Res Hum Retroviruses 1994;10:231-233.
32. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, and Karplus M: CHARMM: A program for macromolecular energy minimization and dynamics calculation. J Comp Chem 1983;4:187-217.
33. Reiher WH: Thesis. Harvard University, 1973.
34. Polygen Corporation Parameter file for CHARMm version 20. Copyright 1986, released August 1988.
35. Steinbach PJ, and Brooks BR: New spherical-cutoff methods for longrange forces in macromolecular simulation. J Comp Chem 1994;15:667-683.
36. Jorgenson WL, Chandrasekhar J, Medura JD, Impey RW, and Klein ML: Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926-935.
37. Steinbach PJ, and Brooks BR: Protein hydration elucidated by molecular dynamics simulation. Proc Natl Acad Sci USA 1993;90: 9135-9139.
38. Leavitt M, and Sharon R: Accurate simulations of protein dynamics in solutions. Proc Natl Acad Sci USA 1988;85:7557-7561.
39. Schulz GE, and Schirmer RH: Principles of Protein Structure. Springer-Verlag, New York, 1979, pp. 74-78.
40. Donaldson YK, Bell JE, Holmes EC, Hughes ES, Brown HK, and Simmonds P: In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop. J Virol 1994;68:5991-6005.
41. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, and Lose EJ: Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992;8:365-393.
42. Tersmette M, de Groede RE, Al BJ, Winkel IM, Gruters RA, Cuypers HT, Huisman HG, and Miedema F: Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-2032.
43. Schuitemaker H, Kootsta NA, de Goede RE, de Wolf F, Miedema F, and Tersmette M: Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991;65:356-363.
44. Roos MTL, Lange JM, de Goede RE, Coutinho RA, Schellekens PT, Miedema F, and Tersmette M: Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis 1992;165:427-432.
45. Zhu T, Mo H, Wang N, Nam, DS, Cao Y, Koup RA, and Ho DD: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261:1179-1181.
46. Connor RI, Mohri H, Cao Y, and Ho DD: Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human-immunodeficiency-virus type 1-infected individuals. J Virol 1993;67:1772-1777.
47. Stenstad T, Magnus JH, Husby G, and Kolset SO: Purification of amyloid-associated heparan sulfate proteoglycans and galactosaminoglycan free chains from human tissues. Scand J Immunol 1993;37:227-235.
48. Murdoch AD, Liu BA, Schwarting R, Tuan RS, and Iozzo RV: Widespread expression of perlecan proteoglycan in basement-membranes and extracellular matrices of human tissues as detected by a novel monoclonal-antibody against domain-III and by in-situ hybridization. J Histochem Cytochem 1994;42:239-249.